Experts from five states have sounded the alarm about blockbuster weight loss drugs like Ozempic leaving users blind, ...

In 2023, research on mice and rats suggested semaglutide — the powerful ingredient behind Wegovy and Ozempic — could raise the risk of one type of thyroid cancer: medullary thyroid cancer (MTC). Last ...

5 MSH Medical School Hamburg University of Applied Sciences and Medical University, Hamburg, Germany Introduction Semaglutide is increasingly used for the treatment of ... Pancreatitis (as defined by ...

The EMA, as well as the FDA in the US, have approved labelling for Wegovy that mentions that semaglutide has been ... people with a family history of thyroid cancer. In a statement, the EMA ...

Animal studies have shown that using semaglutide (the active ingredient in Ozempic) or tirzepatide (the active ingredient in Mounjaro) may increase the risk of thyroid cancer. However, animal ...

Typically, semaglutide is subcutaneously administered ... gallbladder disease, medullary thyroid cancer, or type 2 multiple endocrine neoplasia were excluded from the study. Participants ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

The type 2 diabetes medication, generically known as semaglutide, has received unprecedented ... for conditions ranging from heart disease to cancer to neurodegenerative diseases.

Still, definitely tell your healthcare provider if you have a personal or family history of thyroid cancer before starting semaglutide treatment. It’s possible to experience significant ...

Semaglutide, the active ingredient in Ozempic ... but those with a personal or family history of thyroid cancer should steer clear of the drug. Therefore, if you decide to use Ozempic, be vigilant ...